Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations: A Predictive Model and Nomograms to Aid Clozapine Dose Adjustment and to Assess Compliance in Individual Patients
暂无分享,去创建一个
Amin Rostami-Hodjegan | Geoffrey T Tucker | Robert J Flanagan | G. Tucker | E. P. Spencer | R. Flanagan | A. Rostami-Hodjegan | M. Lennard | Edgar P Spencer | Ajmal M Amin | Martin S Lennard | A. Amin
[1] M. Jann,et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine , 1999, Psychopharmacology.
[2] L. Balant,et al. Therapeutic Drug Monitoring Databases for Postmarketing Surveillance of Drug-Drug Interactions , 2001, Drug safety.
[3] K. Midha,et al. Decomposition of clozapine N-oxide in the qualitative and quantitative analysis of clozapine and its metabolites. , 1994, Journal of pharmaceutical sciences.
[4] D. Ziedonis,et al. Nicotine dependence and schizophrenia. , 1994, Hospital & community psychiatry.
[5] C. Martini,et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients Influence of patient-related variables , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[6] K. Dietz,et al. Therapeutic Drug Monitoring of Clozapine in Relapse Prevention: A Five-Year Prospective Study , 2001, Journal of clinical psychopharmacology.
[7] A. Szegedi,et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. , 1998, Journal of clinical psychopharmacology.
[8] C. Paton,et al. Measurement of clozapine and norclozapine in plasma/serum by high performance liquid chromatography with ultraviolet detection. , 1995, Biomedical chromatography : BMC.
[9] W. Fleischhacker,et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age , 2004, Psychopharmacology.
[10] G. Simpson,et al. Schizophrenia and smoking: an epidemiological survey in a state hospital. , 1995, The American journal of psychiatry.
[11] C. Alm,et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. , 1994, British journal of clinical pharmacology.
[12] J. A. Carrillo,et al. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. , 1998, Journal of clinical psychopharmacology.
[13] D. Goff,et al. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. , 1992, The American journal of psychiatry.
[14] I. Heuser,et al. Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience. , 1999, Pharmacopsychiatry.
[15] E. Perucca,et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics , 2000, Psychopharmacology.
[16] I. Heuser,et al. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight , 2000, Psychopharmacology.
[17] J. Kennedy,et al. CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With Schizophrenia , 2001 .
[18] E. Perucca,et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. , 1999, Therapeutic drug monitoring.
[19] B. Tang,et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. , 2001, Journal of Clinical Psychopharmacology.
[20] G. Tucker,et al. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. , 2002, British journal of anaesthesia.
[21] Jonathan M. Meyer. Individual Changes in Clozapine Levels After Smoking Cessation: Results and a Predictive Model , 2001, Journal of clinical psychopharmacology.
[22] M. Preisig,et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. , 2002, International clinical psychopharmacology.
[23] R. McCarthy. Seizures following Smoking Cessation in a Clozapine Responder , 1994, Pharmacopsychiatry.
[24] P. Neuvonen,et al. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia , 2000, European Journal of Clinical Pharmacology.
[25] J. Rapoport,et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. , 1994, The Journal of clinical psychiatry.
[26] L. Bertilsson,et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.
[27] M. Relling,et al. Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.
[28] A. Mallet,et al. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. , 2003, British journal of clinical pharmacology.
[29] H. Meltzer,et al. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. , 1993, Journal of clinical psychopharmacology.
[30] F. Bressolle,et al. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. , 1998, Journal of clinical psychopharmacology.
[31] R. Kerwin,et al. Active monitoring of 12760 clozapine recipients in the UK and Ireland , 1999, British Journal of Psychiatry.
[32] M. Jann,et al. Lack of CYP3A4 Inhibition by Grapefruit Juice and Ketoconazole upon Clozapine Administration in Vivo , 2001, Drug metabolism and drug interactions.
[33] K. Dietz,et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. , 1998, British journal of clinical pharmacology.
[34] Del D. Miller,et al. The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. , 1991, Therapeutic drug monitoring.
[35] W. Fleischhacker,et al. Influence of patient-related variables on clozapine plasma levels. , 1990, The American journal of psychiatry.
[36] A. Avenoso,et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. , 2000, Pharmacopsychiatry.
[37] S. Marder. Newer antipsychotics in treatment-resistant schizophrenia. , 1999, Biological psychiatry.
[38] E. Leinonen,et al. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. , 1999, Pharmacology & toxicology.
[39] J. Brockmöller,et al. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.
[40] O. Spigset,et al. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. , 2000, British journal of clinical pharmacology.
[41] S. H. Lee,et al. Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability. , 2001, The Journal of clinical psychiatry.
[42] J. Brockmöller,et al. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients , 2000, Psychopharmacology.
[43] Del D. Miller,et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. , 1994, The Journal of clinical psychiatry.
[44] M. Aitkin,et al. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. , 1999, Pharmacogenetics.
[45] U. Fuhr,et al. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. , 1999, Pharmacogenetics.
[46] D. Streiner,et al. Relation of Blood Counts during Clozapine Treatment to Serum Concentrations of Clozapine and Nor-Clozapine , 2002, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[47] L. Bertilsson,et al. Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine: Evidence from a Therapeutic Drug Monitoring Service , 1994, Therapeutic drug monitoring.
[48] J. Fourie,et al. Treatment-Resistance to Clozapine in Association With Ultrarapid CYP1A2 Activity and the C → A Polymorphism in Intron 1 of the CYP1A2 Gene: Effect of Grapefruit Juice and Low-Dose Fluvoxamine , 2001, Journal of clinical psychopharmacology.
[49] P. Neuvonen,et al. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole , 1998, European Journal of Clinical Pharmacology.
[50] McCarthy Rh. Seizures following smoking cessation in a clozapine responder. , 1994 .
[51] Chang-Shin Park,et al. Effect of age and smoking on in vivo CYP1A2, flavin‐containing monooxygenase, and xanthine oxidase activities in Koreans: Determination by caffeine metabolism , 2000, Clinical pharmacology and therapeutics.
[52] C. Alm,et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. , 2000, Therapeutic drug monitoring.
[53] O. Olesen,et al. Contributions of Five Human Cytochrome P450 Isoforms to the N‐demethylation of Clozapine In Vitro at Low and High Concentrations , 2001, Journal of clinical pharmacology.
[54] Stephan Arndt,et al. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram , 1998, Biological Psychiatry.
[55] U. Hofmann,et al. Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis. , 2001, British journal of clinical pharmacology.
[56] D. Collier,et al. Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. , 2000, Pharmacogenetics.